(RTTNews) - French drug giant Sanofi SA (SNYNF, SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Monday that the pivotal Phase 3 LIBERTY ASTHMA QUEST study of dupilumab in a broad ...

Regeneron and its close partner Sanofi have cleared the final mid-stage hurdle for dupilumab in asthma patients, with several doses hitting the trial endpoint both for a subset of patients as well ...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the Phase 3 trial of Dupixent (dupilumab), developed with Sanofi (NASDAQ: SNY), for uncontrolled chronic obstructive pulmonary disease (COPD ...

Regeneron has advanced dupilumab, regarded by many as the company's next big innovation, into a Phase III asthma study, rolling toward an FDA submission behind its lead eczema program.

A phase 3 trial evaluating the efficacy and safety of dupilumab (Dupixent ®; Sanofi US and Regeneron), an interleukin-4 receptor alpha antagonist, in children with uncontrolled moderate to severe ...

Republican presidential candidate Donald Trump said on Monday that if elected he would consider ending a $7,500 tax credit for electric-vehicle purchases and that he would be open to naming Tesla ...

TARRYTOWN, N.Y. and PARIS, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has issued a ...

NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled ...

Dupixent meets early efficacy threshold for continuation in ongoing Phase 3 trial of patients with COPD; second confirmatory trial will commence in third quarter of 2020. Regeneron Pharmaceuticals ...

Sept 11 (Reuters) - Regeneron Pharmaceuticals Inc. Skip to main content. Exclusive news, data and analytics for financial market professionals Learn more about Refinitiv. Skip to main content.